MEDI-GLOBE-GROUP
5.4.2022 17:33:12 CEST | Business Wire | Press release
Medline International B.V., a leading manufacturer and distributor of healthcare supplies in Europe, and Medi-Globe Group, headquartered in Germany, announced today that Medline has entered into a definitive agreement to acquire 100% of shares of ASID BONZ GmbH from Medi-Globe Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005920/en/
ASID BONZ is a leading supplier to hospitals in Germany, offering high-quality surgery, anesthesia, ward-supply and urology products. ASID BONZ was founded in 1811 and is known worldwide for the development of the first anesthetic ether. In 2021, ASID BONZ recorded over 30mio Euros in revenues and served over 1.100 hospitals in Germany.
With similar business models and reputations for outstanding customer service, the two companies have an excellent strategic fit. Looking forward, Medline will make the ASID BONZ brand available outside of Germany to its broad European customer base. Within Germany, the ASID BONZ sales force will have access to Medline products to strengthen their partnership with customers.
“We are excited to increase our product offering and work with this award-winning organization with a renowned customer focus”, said Tripp Amdur, Medline Europe Group President. “Medline is a relatively new player in urology and anesthesia. This acquisition grows our presence in these areas of the hospital. ASID BONZ’s employees, products and service have a long-standing and trusted reputation and this combination will enable us to better meet the needs of our healthcare customers and become a more valued partner”.
Martin Lehner, CEO of Medi-Globe Group adds: “ASID BONZ is known for its unwavering commitment to its customers, providing high-quality medical products that are used to treat patients every day. We are sure that under the ownership of Medline, ASID BONZ will provide substantial avenues of growth in the future. The sale increases Medi-Globe’s focus on the core business - the development and marketing of innovative single-use products for minimally invasive diagnostic and therapeutic procedures”.
Transaction Details
We anticipate the investment will be completed in May 2022 once merger control approval has been obtained and other closing conditions have been fulfilled.
About Medline
With 27,000 employees worldwide and an especially strong presence in North America and Europe, Medline is a leading global healthcare company that manufactures and distributes quality medical and surgical supplies with superior value. Medline takes pride in serving its customers’ needs and improving healthcare around the globe, every day. Medline Europe was established in 2011. Since then, the company has expanded rapidly throughout the continent, serving customers in 27 European countries and with offices, manufacturing and distribution centers across the continent. Learn more about Medline at medline.eu
About Medi-Globe Group
The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Chiemgau, Bavaria, around 70 kilometers south of Munich. Around 670 employees work for the Medi-Globe Group, which was founded in 1990, in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO). More information at www.medi-globe.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005920/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release
Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment
Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release
Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh
BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b
Dubai Culture Unveils ISEA2026 Online Academic Programme3.11.2026 11:58:00 CET | Press release
Dubai Culture and Arts Authority has unveiled the academic programme for the 31st International Symposium on Electronic/Emerging Art (ISEA2026), taking place in Dubai from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data, and Identity’. The symposium will explore the intersections of art, science and technology and examine the future of electronic arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103057351/en/ Dubai Culture unveils ISEA2026 Online Academic Programme (Photo: AETOSWire) The symposium, organised by Dubai Culture in partnership with Zayed University, is set to be the largest edition in its history. It will feature opening remarks by Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and Her Excellency Hala Badri, Director General of Dubai Culture, alongside keynote presentations by Katherine Hayles, Distinguished Research Professor at the U
Komainu Completes Two-Way Digital Asset Transfers for First Abu Dhabi Bank as Institutional Custody Framework Goes Live3.11.2026 10:30:00 CET | Press release
Komainu, a regulated digital asset services provider and custodian backed by Laser Digital and Blockstream, has completed the two-way transfer of a portfolio of digital assets with First Abu Dhabi Bank (FAB) through the institutional digital asset custody framework the two firms have established. The transfers settled instantly. The milestone marks the operationalisation of Komainu’s collaboration with FAB Global Markets, integrating regulated digital asset custody and connectivity capabilities with FAB’s existing infrastructure. The transfers demonstrate the bank’s ability to move digital assets both into and out of the custody environment, validating the infrastructure required to support institutional digital asset activity. The framework has also been designed to support future institutional financing solutions, including lending backed by digital assets held in regulated custody. This provides a foundation for FAB to further integrate digital assets into its financial markets infr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom